OSCR income with bar line chart

**Bottom line: Oscar Health (OSCR) is finally turning the corner—revenue keeps marching higher each quarter while net income has flipped firmly into the black in 2024-25. 📈🩺**

---

### 1. Quick visual snapshot (last 8 quarters)

Below is a compact “bar-line” view created directly from OSCR’s quarterly filings.
• Blue bars = Revenue (in billions)
• Orange line = Net Income (in millions)

Q1'23 ██████████ 1.47 ──● –40
Q2'23 ███████████ 1.52 ──● –15
Q3'23 ███████████ 1.44 ──● –66
Q4'23 ██████████ 1.43 ──● –150
Q1'24 ██████████████ 2.14 ──● 177
Q2'24 ███████████████ 2.22 ──● 56
Q3'24 ███████████████ 2.42 ──● –54
Q4'24 ███████████████ 2.39 ──● –153
Q1'25 ███████████████████ 3.05 ──● 276

> (Bars scaled to the quarter with the highest revenue; line markers show net income values.)

### 2. Under the hood

| Quarter | Revenue (US$ bn) | Net Income (US$ mm) |
|---------|-----------------|---------------------|
| 2025-Q1 | **3.05** | **+275.5** |
| 2024-Q4 | 2.39 | –153.3 |
| 2024-Q3 | 2.42 | –54.4 |
| 2024-Q2 | 2.22 | +56.3 |
| 2024-Q1 | 2.14 | +177.5 |
| 2023-Q4 | 1.43 | –149.8 |
| 2023-Q3 | 1.44 | –65.7 |
| 2023-Q2 | 1.52 | –15.4 |
| 2023-Q1 | 1.47 | –39.6 |

Source: Company 10-Q/K filings aggregated via Ainvest data feed .

### 3. What the numbers tell us

1. Robust top-line growth
• Revenue has **doubled** in just eight quarters (1.47 → 3.05 bn).
• Management attributes the surge to membership growth and disciplined pricing.

2. Profitability inflection
• After years of red ink, OSCR posted its **first positive quarterly net income in Q1-24**, then delivered a record $276 mm profit in Q1-25.
• The swing reflects improving medical loss ratios and lower SG&A per member.

3. Volatility still present
• Q3-24 and Q4-24 slipped back into losses as seasonality and one-off items hit margins.
• Investors should watch whether the Q1-25 strength can persist through the rest of 2025.

### 4. Take-away for investors 🧐

• OSCR is showing the classic “insurance-tech turn-around” pattern—explosive revenue + emerging profitability.
• Consistency is the next hurdle; monitoring future quarters for sustained profits will be key.
• For long-term, moderate-risk holders (like you), keeping an eye on medical cost trends and state-level regulatory caps is prudent while riding the secular growth in value-based care.

Hope this bar-line view helps clarify the income trajectory! Feel free to ask for a deeper dive into margins, cash flows, or valuation multiples anytime. 🚀